IL17A and Alzheimer disease: Therefore, targeting the neutralization of IL-17, regulation of Th17/Treg cell imbalance, nutrition, microbial therapy, and metabolism-regulating drugs may achieve improvement of AD pathophysiology and alleviation of symptoms, providing a new avenue for clinical treatment of AD.